It's worth noting that sibutramine increases pulse rate, and for some obscure reason also tends to increase blood pressure in patients with normal (or low) blood pressure, while reducing BP in hypertensive patients.
So there was at least a slightly muddy cardiac signal in the original sibutramine data that I don't think is being reported to date in the current drugs being studied.
Sibutramine is also quite a bit less efficacious than the Vivus and Orexigen drugs. But maybe that's largely orthogonal to the safety issue.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.